Sharemaestro company-news research for Aspire BioPharma, Inc. (ASBP), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Insufficient evidence
Company news sentiment
Latest ASBP news and sentiment
Aspire BioPharma, Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
Aspire BioPharma, Inc. (NASDAQ: ASBP) Share Price, ASBP Stock News, ASBP Share Price & Updates
kalkine.ca · 17 Sep 2026 20:00
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
1 current stories are mapped specifically to ASBP.
Why there is no score
Confidence is 0/100, below the threshold for a firm score.
—/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news1 company stories
N/A/100
Story agreementrequires at least 2 stories
News history
Daily score and story count over 30 days
11 Sep26 Sep10 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness2
recency-weighted evidenceAgreement0
requires at least 2 storiesPublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 8.3-5.5%
02 Oct 202650USD 8.78+5.5%
25 Sep 202650USD 8.32-2.6%
18 Sep 202650USD 8.54-5.7%
11 Sep 202650USD 9.06+2.1%
04 Sep 202651USD 8.87+4.2%
28 Aug 202651USD 8.51+6.8%
21 Aug 202650USD 7.97+1.5%
Insufficient evidence
News subjects
What is shaping the score
Market update501 stories · 100%
Source mix
Where the evidence comes from
kalkine.ca501 stories · 100%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral10 Oct 17:19
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 10 Oct 17:19 | 50 | +0 | 0/100 (-16) | 1 (-8) | Insufficient |
| 17 Sep 23:59 | 50 | +0 | 16/100 (-2) | 9 (-4) | Provisional |
| 09 Sep 23:59 | 50 | +0 | 18/100 (0) | 13 (-4) | Provisional |
| 08 Sep 23:59 | 50 | -1 | 18/100 (-7) | 17 (0) | Provisional |
| 28 Aug 23:59 | 51 | +0 | 25/100 (-5) | 17 (-6) | Provisional |
| 24 Aug 23:59 | 51 | +1 | 30/100 (+12) | 23 (0) | Provisional |
| 23 Aug 23:59 | 50 | +0 | 18/100 (-2) | 23 (-3) | Provisional |
| 19 Aug 23:59 | 50 | +0 | 20/100 (-8) | 26 (-2) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 1 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Aspire BioPharma, Inc. (NASDAQ: ASBP) Share Price, ASBP Stock News, ASBP Share Price & Updates
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 20:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Earlier company news
ASBP news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 43 older ASBP headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ASBP, but the headline and available text are not mainly about Aspire BioPharma, Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
22Jul 2026
Provider mentionNot included in score
Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing
(RTTNews) - Today's top biotech gainers include Wellgistics following its rebranding, Femasys, which recently resolved its Nasdaq compliance issue, Vor Bio with continued progress in its Telitacicept program, and Sol-Gel Technologies as investors look ahead to key SGT-610 Phase 3 data, am…
Article detailsWhy it was excluded
(RTTNews) - Today's top biotech gainers include Wellgistics following its rebranding, Femasys, which recently resolved its Nasdaq compliance issue, Vor Bio with continued progress in its Telitacicept program, and Sol-Gel Technologies as investors look ahead to key SGT-610 Phase 3 data, among others. Read on… WGRX Rebranded Wellgistics Health Inc. (WGRX) was one of the top gainers on Tuesday, as the company announced the completion of its name change to DataMEDS AI, Inc. The company will begin trading under the stock symbol 'MEDS' on the NASDAQ Capital Market stock exchange on Wednesday, July 2
- Published
- 22 Jul 2026 04:20
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
BiotechClinical TrialsFda ApprovalFourth QuarterNasdaq ComplianceNet Income
21Jul 2026
Provider mentionNot included in score
16-Time X Games Medalist Jarryd McNeil Joins BUZZ BOMB
Aspire Biopharma's subsidiary, Buzz Bomb Caffeine Company, has signed 16-time X Games medalist Jarryd McNeil as a Global Brand Ambassador for its BUZZ BOMB™ single-serve caffeine powder line. McNeil will promote the brand across his tours, competitions, and social media, while BUZZ BOMB™ …
Article detailsWhy it was excluded
Aspire Biopharma's subsidiary, Buzz Bomb Caffeine Company, has signed 16-time X Games medalist Jarryd McNeil as a Global Brand Ambassador for its BUZZ BOMB™ single-serve caffeine powder line. McNeil will promote the brand across his tours, competitions, and social media, while BUZZ BOMB™ aims to provide fast-acting energy to athletes with its innovative under-the-tongue stick packs. The partnership saw a positive market reaction, with ASBP stock gaining 5.45% in the July 20th session.
- Published
- 21 Jul 2026 19:41
- Provider record
- alphavantage
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
FinanceLife Sciences
20Jul 2026
Provider mentionNot included in score
Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)
Aspire Biopharma Holdings, Inc.'s subsidiary Buzz Bomb Caffeine Company LC has announced a partnership with multi-time X Games medalist and freestyle motocross legend Jarryd McNeil. McNeil will serve as a global brand ambassador for the BUZZ BOMB™ caffeine product line, integrating the br…
Article detailsWhy it was excluded
Aspire Biopharma Holdings, Inc.'s subsidiary Buzz Bomb Caffeine Company LC has announced a partnership with multi-time X Games medalist and freestyle motocross legend Jarryd McNeil. McNeil will serve as a global brand ambassador for the BUZZ BOMB™ caffeine product line, integrating the branding into his touring schedule, events, and social media, and featuring in upcoming marketing campaigns. This collaboration aims to strengthen BUZZ BOMB™'s presence in action sports by aligning with McNeil's high-energy lifestyle and market reach.
- Published
- 20 Jul 2026 13:40
- Provider record
- alphavantage
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 3 consolidated
Life SciencesRetail Wholesale
19Jul 2026
Provider mentionNot included in score
Source lookup
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
Article detailsWhy it was excluded
- Published
- 19 Jul 2026 06:06
- Provider record
- snapshot
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
04Jul 2026
Provider mentionNot included in score
Source lookup
Alois Rubenbauer reports 65,000 shares in Aspire Biopharma (ASBP) Schedule 13G
Article detailsWhy it was excluded
- Published
- 4 Jul 2026 05:52
- Provider record
- snapshot
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.